Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuel Rodrigues

Showing results (161-170 of 199) with videos related to

Pageof 20
Sort By:
BMC Medical Informatics and Decision Making|February 22, 2017
The effect of a test ordering software intervention on the prescription of unnecessary laboratory tests - a randomized controlled trialCarlos Manuel Silva Martins, Andreia Sofia da Costa Teixeira, Luís Filipe Ribeiro de Azevedo, et al.
The Cleft Palate-Craniofacial Journal : Official Publication of the American Cleft Palate-Craniofacial Association|January 4, 2022
Adapting Elements of Cleft Care Protocols in Low- and Middle-income Countries During and After COVID-19: A Process-driven Review With RecommendationsMatthew Fell, Michael Goldwasser, B S Jayanth, et al.
The Lancet. Oncology|July 21, 2018
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trialMichael Friedlander, Val Gebski, Emma Gibbs, et al.
Nature Communications|May 16, 2018
Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumorsManuel Rodrigues, Lenha Mobuchon, Alexandre Houy, et al.
Nature Communications|October 14, 2024
Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafuspManuel Rodrigues, Toulsie Ramtohul, Aurore Rampanou, et al.
European Journal of Cancer (Oxford, England : 1990)|July 21, 2022
MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patientsMathilde Saint-Ghislain, Anne-Céline Derrien, Lionnel Geoffrois, et al.
European Journal of Cancer (Oxford, England : 1990)|July 22, 2021
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapyAngelina Tjokrowidjaja, Michael Friedlander, Sarah J Lord, et al.
Gynecologic Oncology|August 15, 2022
Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohortQuentin Dominique Thomas, Amal Boussere, Jean-Marc Classe, et al.
Current Oncology (Toronto, Ont.)|October 27, 2023
Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility StudyFariba Nemati, Leanne de Koning, David Gentien, et al.
The Journal of Experimental Medicine|April 2, 2024
Divergent local and systemic antitumor response in primary uveal melanomasFrancesca Lucibello, Ana I Lalanne, Anne-Laure Le Gac, et al.
Pageof 20

Showing results (161-170 of 199) with videos related to

Sort By:
Pageof 20
BMC Medical Informatics and Decision Making|February 22, 2017
The effect of a test ordering software intervention on the prescription of unnecessary laboratory tests - a randomized controlled trialCarlos Manuel Silva Martins, Andreia Sofia da Costa Teixeira, Luís Filipe Ribeiro de Azevedo, et al.
The Cleft Palate-Craniofacial Journal : Official Publication of the American Cleft Palate-Craniofacial Association|January 4, 2022
Adapting Elements of Cleft Care Protocols in Low- and Middle-income Countries During and After COVID-19: A Process-driven Review With RecommendationsMatthew Fell, Michael Goldwasser, B S Jayanth, et al.
The Lancet. Oncology|July 21, 2018
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trialMichael Friedlander, Val Gebski, Emma Gibbs, et al.
Nature Communications|May 16, 2018
Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumorsManuel Rodrigues, Lenha Mobuchon, Alexandre Houy, et al.
Nature Communications|October 14, 2024
Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafuspManuel Rodrigues, Toulsie Ramtohul, Aurore Rampanou, et al.
European Journal of Cancer (Oxford, England : 1990)|July 21, 2022
MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patientsMathilde Saint-Ghislain, Anne-Céline Derrien, Lionnel Geoffrois, et al.
European Journal of Cancer (Oxford, England : 1990)|July 22, 2021
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapyAngelina Tjokrowidjaja, Michael Friedlander, Sarah J Lord, et al.
Gynecologic Oncology|August 15, 2022
Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohortQuentin Dominique Thomas, Amal Boussere, Jean-Marc Classe, et al.
Current Oncology (Toronto, Ont.)|October 27, 2023
Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility StudyFariba Nemati, Leanne de Koning, David Gentien, et al.
The Journal of Experimental Medicine|April 2, 2024
Divergent local and systemic antitumor response in primary uveal melanomasFrancesca Lucibello, Ana I Lalanne, Anne-Laure Le Gac, et al.
Pageof 20